Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported interim clinical data of BPX-501 in pediatric patients with acute myeloid leukemia (AML) and primary immunodeficiencies (PIDs). BPX-501 is an adjunct T cell therapy incorporating CaspaCIDe® administered after haploidentical hematopoietic stem cell transplant (haplo-HSCT) for the treatment of hematologic cancers and inherited blood diseases.
The FDA has slapped a clinical hold on a combo therapy using Advaxis’$ADXS axalimogene filolisbac along with AstraZeneca’s approved PD-L1 Imfinzi following the death of a patient in their Phase I/II trial.
Celgene has been slammed with a refuse-to-file letter from the FDA for ozanimod, the biggest late-stage drug it has in the pipeline.
Gilead’s Kite is linking with Sangamo Therapeutics in a collaboration that aims to develop next-generation engineered cell therapies for the treatment of cancer.
Edmond De Rothschild Investment Partners has raised €345 million ($430 million) for its latest fund. The haul makes BioDiscovery 5 the largest fund dedicated to biotechs and medical devices in Europe and tees up Edmond De Rothschild to invest in 15 to 17 companies.
Researchers say the approach breaks new ground in treating cancer non-invasively and with unprecedented precision.
Edinburgh, Scotland based Synpromics has teamed up with UCL Great Ormond Street Institute of Child Health to develop novel gene therapies for diseases affecting the haematopoietic system.
Tmunity Therapeutics is looking to bring better and safer T-cell therapies for both solid tumors and blood cancers and has scored a $100 million series A to propel it on its journey
Celgene agreed on Monday to buy the rest of Juno Therapeutics it doesn't already own for about $9 billion in cash to gain access to Juno's pipeline of CAR-T cancer drugs.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.